Patents by Inventor Mark Shenderovich

Mark Shenderovich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arf6 inhibitors and methods of synthesis and use thereof
    Patent number: 10849901
    Abstract: Disclosed herein are compounds and methods for inhibiting Arf6. Pharmaceutical compositions and methods for treating a subject with an inhibitor of Arf6 are also disclosed herein.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: December 1, 2020
    Assignees: Navigen, Inc., The University of Utah Research Foundation
    Inventors: Kirill Ostanin, Mark Shenderovich, Ashok Bajji, Christopher L. Cioffi, Neil Moss, Hariprasad Vankayalapati, Dean Li
  • ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF
    Publication number: 20170189405
    Abstract: Disclosed herein are compounds and methods for inhibiting Arf6. Pharmaceutical compositions and methods for treating a subject with an inhibitor of Arf6 are also disclosed herein.
    Type: Application
    Filed: May 27, 2015
    Publication date: July 6, 2017
    Applicants: Navigen, Inc., The University of Utah Research Foundation
    Inventors: Kirill Ostanin, Mark Shenderovich, Ashok Bajji, Christopher L. Cioffi, Neil Moss, Hariprasad Vankayalapati, Dean Li
  • Purine-core inhibitors of HSP90 and their use in treating cancer
    Patent number: 8476285
    Abstract: The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L1, L2, are as defined herein.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: July 2, 2013
    Assignee: Myrexis, Inc.
    Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER
    Publication number: 20100016586
    Abstract: The invention relates to compounds of Formulae I-III and their therapeutic uses.
    Type: Application
    Filed: June 30, 2009
    Publication date: January 21, 2010
    Applicant: Myriad Genetics, Incorporated
    Inventors: ASHOK C. BAJJI, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • Therapeutic compounds and their use in cancer
    Patent number: 7595401
    Abstract: The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: September 29, 2009
    Assignee: Myriad Pharmaceuticals, Inc.
    Inventors: Ashok C. Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark B. Anderson, Daniel Wettstein, Mark Shenderovich, John A. Vanecko
  • 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases
    Publication number: 20080070867
    Abstract: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. The compounds for use in the compositions and methods provided herein have formulae (I) Protein tyrosine phosaphatase, including PTB-IB, mediated diseases and disorders include diabetes including Type 1 and Type 2 diabetes (and associated complications such as hypertension, ischemic diseases of the large and small blood vessels, blindness, circulatory problems, kidney failure and atherosclerosis), syndrome X, metabolic syndrome, glucose intolerance, insulin resistance, obesity, cancer, and neurodegenerative diseases.
    Type: Application
    Filed: January 17, 2006
    Publication date: March 20, 2008
    Applicant: Metabasis Therapeutics, Inc.
    Inventors: Zacharia Cheruvallath, Joseph Semple, Vasanthakumar Rajappan, Darryl Rideout, Venkatachalapathi Yalamoori, Chung-Ying Tsai, Feiyue Wu, Lars Thoresen, Mark Shenderovich
  • THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER
    Publication number: 20070299258
    Abstract: The invention relates to compounds of Formulae I-III and their therapeutic uses.
    Type: Application
    Filed: May 14, 2007
    Publication date: December 27, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Ashok Bajji, Se-Ho Kim, Benjamin Markovitz, Richard Trovato, Rajendra Tangallapally, Mark Anderson, Daniel Wettstein, Mark Shenderovich, John Vanecko
  • Inhibitors of anthrax lethal factor
    Publication number: 20070197577
    Abstract: Methods, compounds and compositions for preventing and treating anthrax infections by inhibiting Anthrax Lethal Factor (LF) activity.
    Type: Application
    Filed: March 17, 2004
    Publication date: August 23, 2007
    Applicant: Cengent Therapeutics
    Inventors: Darryl Rideout, Tseitin Vladimir, Mark Shenderovich, Edward Semple, Ruth Nutt, Yalamoori Venkatachalapathl, Tsai Chung-Ying, Michelle De Luna, Thomas Brady, Feiyue Wu
  • Trisubstituted nitrogen modulators of tyrosine phosphatases
    Publication number: 20060135773
    Abstract: Compounds, compositions and methods are provided for modulating the activity of protein tyrosine phosphatases, including PTP-1B. In one embodiment, the compounds are N,N-dibenzylarylsulfonamides.
    Type: Application
    Filed: June 17, 2005
    Publication date: June 22, 2006
    Inventors: Joseph Semple, Darryl Rideout, Ruth Nutt, Mark Shenderovich, Jing Wang, Shankari Mylvaganam, Feiyue Wu, Chung Tsai, Venkatachalapathi Yalamoori, Colin Loweth
  • Inhibitors of anthrax lethal factor activity
    Patent number: 6436933
    Abstract: Methods and compositions that act as specific inhibitors of ALF activity for the prophylaxis and treatment of anthrax infections.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: August 20, 2002
    Assignee: Structural Bioinformatics Inc.
    Inventors: Darryl Rideout, Venkatachalapathi V. Yalamoori, Kalyanaraman Ramnarayan, Mark Shenderovich, Jian Hua Zheng, Jason Sun, Christina Niemeyer